EMC, Jazz Pharma: Analysts' New Ratings
Editor's Note: Green and red arrows refer to intraday stock price movement.
NEW YORK (TheStreet) -- CHANGE IN RATINGS
Amyris (AMRS) upgraded at Morgan Stanley from Equal-weight to Overweight. $32 price target. Company continues to execute on its growth strategy.
Cameron International (CAM) upgraded at Credit Suisse from Neutral to Outperform. $73 price target. Very strong orders.
EMC (EMC) upgraded at Oppenheimer from Perform to Outperform. $32 price target. Stock is attractive, following a recent pullback. East West Bancorp (EWBC) upgraded at FBR from Market Perform to Outperform. $23 price target. Stock is attractively valued, following a recent pullback. Exelon (EXC) upgraded at UBS from Neutral to Buy. $50 price target. Cost synergy story and leverage to power recovery. Jazz Pharmaceuticals (JAZZ) upgraded at Jefferies to Buy. $52 price target. Estimates also upped, given recent Xyrem growth. Oceaneering International (OII) downgraded at Credit Suisse from Outperform to Neutral. $48 price target. Central theses played out. Oil States (OIS) upgraded at Credit Suisse from Neutral to Outperform. $110 price target. Stock should continue to deliver higher earnings. Rockwell Automation (ROK) upgraded at Baird from Neutral to Outperform. $92 price target. Company can continue to deliver solid growth over the coming years. RadioShack (RSH) upgraded at Goldman from Neutral to Buy. Company was also added to the Conviction Buy list. $18 price target. Company is improving its position in the wireless market. Vanguard Health (VHS) rated new Overweight at JP Morgan. $22 price target. Company has attractive exposure to urban markets. Vodafone (VOD) upgraded at UBS from Neutral to Buy. $31.05 price target. VZW dividend larger than expected. Vertex Pharmaceuticals (VRTX) upgraded at Citigroup from Hold to Buy. $60 price target. Incivek should not disappoint.End of report.
Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Dividend Stock Advisor
TRY IT FREENew! $49.95/yr
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Real Money
TRY IT FREE24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
Product Features:
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV
